Kinea Bio secures $1.1M from the Jain Foundation to advance gene therapy for dysferlinopathy. This funding will support critical preclinical studies and accelerate the development of KNA-155.

Sep 23, 2025•3 days ago

Amount Raised

$1.1 Million

SeattleBiotechnologyHealth Care

Investors

Jain Foundation

Description

Kinea Bio announced a $1.1 million commitment from the Jain Foundation to support preclinical studies for its gene therapy KNA-155 targeting dysferlinopathy. This investment is contingent upon the achievement of certain milestones. Additionally, Kinea received a strategic license from Solid Biosciences for its AAV-SLB101 capsid. These developments provide a solid foundation for advancing their gene therapy program.

Company Information

Company

Kinea Bio

Location

Seattle, Washington, United States

About

Kinea Bio is a patient-focused biotechnology company striving to accelerate the development of next-generation AAV-based gene therapies to treat neuromuscular diseases. Kinea is developing an integrated technology platform designed to address the most critical challenges facing the field of gene therapy, including novel targeting and gene regulation technologies, advanced engineered tissue modeling capabilities, and strategies that will enable delivery of larger, more functional therapeutic cargos that has previously been possible.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns